Eyevensys Receives Investment From Boehringer Ingelheim
Eyevensys said it received an equity investment from the Boehringer Ingelheim Venture Fund. Further details were not available. The company raised about $2.1 million in its first round of funding in January 2012. It said early investors - Innobio, managed by CDC Entreprises; Inserm Transfert Initiative; and CapDecisif Management - plan to participate in the second round.
12 April 2013•4 mins read
